Status:

ACTIVE_NOT_RECRUITING

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Lead Sponsor:

University of Alabama at Birmingham

Collaborating Sponsors:

Congressionally Directed Medical Research Programs

Conditions:

Gulf War Illness

Eligibility:

All Genders

45+ years

Phase:

NA

Brief Summary

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a de...

Detailed Description

The project is funded by the Congressionally Directed Medical Research Programs (CDMRP) of the U.S. Department of Defense. The study uses a prospective, pseudo-randomized, placebo-controlled, blinded...

Eligibility Criteria

Inclusion

  • In accordance with the Institute of Medicine (IOM) 2014 guidance, participants must meet both the Kansas and CDC (Centers for Disease Control and Prevention) Case Definitions of GWI. Participants must have been deployed to the Persian Gulf Region during the 1990-1991 Gulf War, meet symptom domain criteria, and not have exclusionary medical conditions. The case definitions will be used for inclusionary screening purposes.
  • Meets Kansas GWI Case Definition
  • Meets CDC GWI Case Definition
  • Able to commit to a 10-month study

Exclusion

  • Currently involved in an experimental treatment study
  • Abnormal liver function values
  • Abnormal kidney function values
  • Currently pregnant
  • Blood clotting disorder (contraindicated with all three botanicals)
  • Reported diagnosis of diabetes with an A1C greater than 9
  • The use of contraindicated medications (see below):
  • Anticoagulant medications (such as warfarin, heparin, etc.)
  • Lithium
  • Tacrolimus (Prograf)
  • Cancer medications (Alkylating agents, antitumor antibiotics, Topoisomerase I inhibitors, Tamoxifen)

Key Trial Info

Start Date :

May 31 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2026

Estimated Enrollment :

390 Patients enrolled

Trial Details

Trial ID

NCT05377242

Start Date

May 31 2023

End Date

June 30 2026

Last Update

November 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233